The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

emphasizes the importance of proactive vision care and early detection in the fight against this life-altering disease. "While many people associate AMD with old age, we believe the key to ...

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to ...

The company offers year-round educational services on the conditions, using this month in particular to guide patients to ...